Coverage in The Australian

Interesting commentary by Rebecca Urban in The Australian this morning. A big thank you to the hundreds of people from the Australian biosciences industry who reached out in personal support over the past few weeks. I actually wish Chris Roberts every success. Notwithstanding my views on the product, if anyone should be able to fix the company’s corporate governance,…

IRESSt My Case

Some of you correctly read between the lines of David Langsam’s (Biotech Daily) perfunctory reporting last week, and ascertained that I was pissed off at him. I was, though in truth I probably shouldn’t have been. The problem is that David uses CommSecIRESS financial markets software for his share market reporting activities because he thinks that…

Wolf Bait : an Analysis of an Analysis (ASX : NRT)

Last Friday Lodge Partners initiated coverage on Novogen (ASX : NRT). Many readers have been anxiously waiting for me to comment on Marc Sinatra’s research report and I have certainly been watching the share trading platforms where there has been a moderate level of “high-fiving.” Probably the most intelligent comment I saw was on HotCopper where…

Novogen : Unacceptable Behaviour (Part I)

I have previously expressed my highly negative opinion about company executives that informally engage with shareholders through “permitted” 3rd party communications on trading platforms such as HotCopper and Sharetrader Forum. By this, I mean when an (apparently) influential shareholder reaches out to a senior executive, possibly even the CEO or Chairman (in the case of…

Cock-a-doodle-doo…

I’m abroad at the moment and I have been getting up very early each day to try and catch up on the morning news back in Australia. Fortunately, a lot of people have also been helping me to stay on top of news flow while I am away and several people forwarded me Tony Boyd’s…

No Fingernails Left : Prima Biomed

This, my friends, is a cliff: And this is a cliffhanger : We have been witness to an extraordinary couple of days in the life of Prima Biomed (ASX:PRR). Not only was the initial ASX pop on the CVac announcement, quite frankly stunning, but the ADR traffic has been phenomenal. It’s too early to tell…